Brief: Aura Biosciences To Present Preclinical Data Demonstrating Applicability Of AU-011 In Bladder Cancer At 2022 ASCO Genitourinary Cancer Symposium
14/02/2022 22:06
Feb 14 (Reuters) - Aura Biosciences Inc AURA.O :
* AURA BIOSCIENCES TO PRESENT PRECLINICAL DATA DEMONSTRATING APPLICABILITY
OF
AU-011 IN BLADDER CANCER AT 2022 ASCO GENITOURINARY CANCER SYMPOSIUM
* AURA BIOSCIENCES INC - COMPANY ON TRACK TO INITIATE PHASE 1 CLINICAL TRIAL
IN 2H
2022
Source text for Eikon: ID:nBwbk9XVka
Further company coverage: AURA.O
Recent news on Aura Biosciences
See all newsBrief: Aura Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Aura Biosciences - May Offer Securities Up To $500 Million Aggregate
Brief: Aura Biosciences Reports Second Quarter 2026 Financial Results And Recent Business Highlights
U.S. RESEARCH ROUNDUP-Aecom, Humana, Mosaic
Aura Biosciences Q1 net loss widens on higher R&D costs